Influenza vaccines 2024-2025 – AIFA approval

The Italian Agency for Drugs (AIFA) has announced the authorisation of eight vaccines for the 2024-2025 season, updated based on recommendations from the World Health Organisation (WHO). In light of the potential escalation of the influenza virus, as indicated by virologists and family doctors, it is imperative to prioritize vaccination as a means of safeguarding the well-being of vulnerable populations, particularly individuals aged 60 and above, pregnant women, infants and children between the ages of 6 months and 6 years, along with those afflicted with pre-existing medical conditions. The seasonal influenza vaccines for the 2024-2025 period encompass both products authorised under the mutual recognition procedure and those approved under the centralised procedure, which is coordinated by the European Medicines Agency (EMA).